Gerresheimer has announced plans to expand its production capacities for medical systems in the US, with an investment of around €166m ($180m).
The investment will see the expansion of Gerresheimer’s facility in Peachtree City, Georgia, by approximately 18,000m² (194,000ft²).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Planned to be carried out in two stages, the expansion plan aims to enhance the company’s capabilities to manufacture products like inhalers and autoinjectors.
Currently, Gerresheimer employs about 270 people at the Peachtree City site and the plan is expected to create over 400 new jobs.
The site manufactures medical devices including inhalers, infusion set components, microinjectors, microbiological test cards, and autoinjectors, which are used for conditions such as diabetes and obesity.
In the first expansion phase, a new 7,700m² (83,000ft²) building section is being constructed adjacent to the existing plant, with 5,000m² designated for ISO 14644-1 cleanroom class 9 production areas.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe installation of specialised production technology will commence in the second half of 2024, with production ramp-up expected by the year-end.
The new building also includes an automated high-bay warehouse.
Once the first phase is complete, the site will have approximately 12,000m² of cleanroom class 8 and 9 production space.
The second phase involves constructing a new 10,200m² factory near Atlanta Regional Airport, about 2.6km from the first site.
This facility will add 7,200m² of cleanroom class 9 production space and another automated high-bay warehouse.
Construction will soon commence following the preparatory work, with production expected to start by the end of next year. The site also allows for future expansions.
Gerresheimer CEO Dietmar Siemssen said: “North America is an important growth market for us. The expansion of the site in Peachtree City is of great importance for our medical device business in the USA.
“The expansion of this site is therefore currently one of the key projects in our global capacity expansions based on long-term customer contracts.”
